United States· US:76431-120_76014f22-a52f-486b-a265-177b6403c907
Juxtapid
A lomitapide product containing lomitapide mesylate, registered in United States by Amryt Pharmaceuticals DAC. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Lomitapide is registered in 14 of 19 countries.
Countries holding a registration under ATC C10AX12 (lomitapide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Lomitapide · ATC C10AX12
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LOMITAPIDE MESYLATE
- Manufacturer
- Amryt Pharmaceuticals DAC
- Country
- United States (US)
- ATC code
- C10AX12
- ATC class
- Lomitapide
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc11764311200128 CAPSULE in 1 BOTTLE (76431-120-01)
- ndc1176431-120-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
299 interactions on record for lomitapide.
Graded by severity as the source publishes them — 206 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lomitapide · interactions on record
299 records
- 206 severe
- 86 moderate
- 7 minor
Most severe, free to view
- ClotrimazoleA01AB18severe
- AprepitantA04AD12severe
- Chenodeoxycholic acidA05AA01severe
- SulfasalazineA07EC01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lomitapide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaJUXTAPIDCHIESI FARMACEUTICI S.P.A.
- CzechiaLOJUXTAChiesi Farmaceutici S.p.A., Parma
- SpainLOJUXTA 20 MG CAPSULAS DURASChiesi Farmaceutici S.P.A.
- FinlandLojuxtaChiesi Farmaceutici S.p.A.
- FranceLOJUXTA 20 mg, gélulesCHIESI FARMACEUTICI
- United KingdomLojuxta 20mg capsulesChiesi Ltd
- BelgiumLojuxta 20 mgChiesi Farmaceutici
- IcelandLojuxtaChiesi Farmaceutici S.p.A.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lojuxta
- Liechtenstein · Lojuxta
- Norway · Lojuxta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9c251346-a3b6-40ff-97e4-f4efe60cb5ba GET /v1/drugs/9c251346-a3b6-40ff-97e4-f4efe60cb5ba?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "20",
"substance": "LOMITAPIDE MESYLATE",
"productndc": "76431-120",
"dosage_form": "CAPSULE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA203858",
"marketing_category": "NDA"
}See everything about lomitapide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.